Vireo Growth (VREOF) Current Deferred Revenue (2020 - 2026)
Vireo Growth's (VREOF) quarterly Current Deferred Revenue came in at $4.3 million in Q1 2026, up 260.28% year-on-year from $1.2 million in Q1 2025, and down 8.51% quarter-over-quarter from $4.7 million in Q4 2025.
Vireo Growth (VREOF) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Vireo Growth has disclosed Current Deferred Revenue across 7 years of filings, most recently posting $4.3 million for Q1 2026.
- Current Deferred Revenue for Q1 2026 came in at $4.3 million, up 260.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.3 million (up 260.28% YoY), and the FY2025 annual result was $4.7 million, up 346.07% from the prior year.
- Current Deferred Revenue came in at $4.3 million for Q1 2026 at Vireo Growth, down from $4.7 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $4.7 million in Q4 2025 to a low of $450334.0 in Q1 2022.
- The 5-year median for Current Deferred Revenue is $833832.0 (2023), against an average of $1.4 million.
- Across the five-year window, Current Deferred Revenue increased 13.22% in 2023 and surged 346.07% in 2025, its largest moves.
- Vireo Growth's Current Deferred Revenue stood at $684703.0 in 2022, then advanced by 21.78% to $833832.0 in 2023, then climbed by 26.36% to $1.1 million in 2024, then soared by 346.07% to $4.7 million in 2025, then retreated by 8.51% to $4.3 million in 2026.
- The last three Current Deferred Revenue figures came in at $4.3 million (Q1 2026), $4.7 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Vireo Growth | - | - | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.30 Mn |
| Dec 31, 2025 | 4.70 Mn |
| Sep 30, 2025 | 2.46 Mn |
| Jun 30, 2025 | 2.43 Mn |
| Mar 31, 2025 | 1.19 Mn |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 921,785.00 |
| Jun 30, 2024 | 821,761.00 |
| Mar 31, 2024 | 885,696.00 |
| Dec 31, 2023 | 833,832.00 |
| Sep 30, 2023 | 732,775.00 |
| Jun 30, 2023 | 626,689.00 |
| Mar 31, 2023 | 710,117.00 |
| Dec 31, 2022 | 684,703.00 |
| Sep 30, 2022 | 647,208.00 |
| Jun 30, 2022 | 522,926.00 |
| Mar 31, 2022 | 450,334.00 |
| Dec 31, 2021 | 409,627.00 |
| Sep 30, 2021 | 424,448.00 |
| Jun 30, 2021 | 374,498.00 |